You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
Merck
AstraZeneca
Boehringer Ingelheim

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TALAZOPARIB TOSYLATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Talazoparib Tosylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02282345 Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation Recruiting Medivation, Inc. Phase 2 2015-04-01 The goal of this clinical research study is to learn if talazoparib can help to control breast cancer that has a BRCA mutation (genetic change). The safety of talazoparib will also be studied.
NCT02282345 Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation Recruiting M.D. Anderson Cancer Center Phase 2 2015-04-01 The goal of this clinical research study is to learn if talazoparib can help to control breast cancer that has a BRCA mutation (genetic change). The safety of talazoparib will also be studied.
NCT02286687 Phase II Study of BMN 673 Active, not recruiting BioMarin Pharmaceutical Phase 2 2014-12-01 The goal of this clinical research study is to learn if talazoparib can help to control advanced cancer in patients who have a specific type of alteration. The safety of this drug will also be studied.
NCT02286687 Phase II Study of BMN 673 Active, not recruiting M.D. Anderson Cancer Center Phase 2 2014-12-01 The goal of this clinical research study is to learn if talazoparib can help to control advanced cancer in patients who have a specific type of alteration. The safety of this drug will also be studied.
NCT02316834 POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer Active, not recruiting BioMarin Pharmaceutical Phase 0 2015-06-01 The goal of this clinical research study is to learn about the effects of BMN 673 on ovarian, Fallopian tube, and peritoneal cancer. Researchers want to find out if certain characteristics of the DNA (the genetic material in cells) affect how the disease responds to therapy with BMN 673 and if treatment with BMN 673 affects the genetic material in cancer cells.
NCT02316834 POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer Active, not recruiting M.D. Anderson Cancer Center Phase 0 2015-06-01 The goal of this clinical research study is to learn about the effects of BMN 673 on ovarian, Fallopian tube, and peritoneal cancer. Researchers want to find out if certain characteristics of the DNA (the genetic material in cells) affect how the disease responds to therapy with BMN 673 and if treatment with BMN 673 affects the genetic material in cancer cells.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Talazoparib Tosylate

Condition Name

Condition Name for Talazoparib Tosylate
Intervention Trials
HER2/Neu Negative 1
Stage IV Lung Cancer AJCC v8 1
Fallopian Tube Cancer 1
Refractory Acute Myeloid Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Talazoparib Tosylate
Intervention Trials
Breast Neoplasms 2
Neoplasms 1
Leukemia 1
Lung Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Talazoparib Tosylate

Trials by Country

Trials by Country for Talazoparib Tosylate
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Talazoparib Tosylate
Location Trials
Texas 3
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Talazoparib Tosylate

Clinical Trial Phase

Clinical Trial Phase for Talazoparib Tosylate
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 1
Phase 0 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Talazoparib Tosylate
Clinical Trial Phase Trials
Not yet recruiting 2
Recruiting 2
Active, not recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Talazoparib Tosylate

Sponsor Name

Sponsor Name for Talazoparib Tosylate
Sponsor Trials
M.D. Anderson Cancer Center 3
National Cancer Institute (NCI) 3
BioMarin Pharmaceutical 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Talazoparib Tosylate
Sponsor Trials
Other 6
Industry 3
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Merck
Harvard Business School
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.